rs1131690907
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000321.3(RB1):c.264+1G>A variant causes a splice donor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000321.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- hereditary retinoblastomaInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, G2P, Ambry Genetics
- retinoblastomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- melanomaInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| RB1 | NM_000321.3 | c.264+1G>A | splice_donor_variant, intron_variant | Intron 2 of 26 | ENST00000267163.6 | NP_000312.2 | ||
| RB1 | NM_001407165.1 | c.264+1G>A | splice_donor_variant, intron_variant | Intron 2 of 26 | NP_001394094.1 | |||
| RB1 | NM_001407166.1 | c.264+1G>A | splice_donor_variant, intron_variant | Intron 2 of 16 | NP_001394095.1 | |||
| RB1 | NM_001407167.1 | c.264+1G>A | splice_donor_variant, intron_variant | Intron 2 of 2 | NP_001394096.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Retinoblastoma Pathogenic:2
Case and Pedigree Information: BILATERAL CASES:1, UNILATERAL CASES:0, TOTAL CASES:1, PEDIGREES:1. ACMG Codes Applied:PVS1, PM2 -
ClinVar contains an entry for this variant (Variation ID: 428734). This sequence change affects a donor splice site in intron 2 of the RB1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RB1 are known to be pathogenic (PMID: 17096365). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with bilateral retinoblastoma (PMID: 15884040; Invitae). This variant is also known as c.402+1G>A. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.264+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 2 of the RB1 gene. This alteration, referred to as c.402+1G>A, was identified in a patient with bilateral retinoblastoma (RB) (Nichols KE, Hum. Mutat. 2005 Jun; 25(6):566-74). In addition, two other alterations at the same location (c.264+1G>C and c.264G>T, referred to as IVS2+1G>C and IVS2+1G>T respectively) were identified in patients with bilateral RB (Zhang K, Hum. Mutat. 2008 Apr; 29(4):475-84; Choy KW, Hum. Mutat. 2002 Nov; 20(5):408). Using the BDGP and ESEfinder splice site prediction tools, the c.264+1G>A alteration is predicted to abolish the native splice donor site; however, direct experimental evidence is unavailable. In addition to the clinical data presented in the literature, since alterations that disrupt the canonical splice donor site are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at